Article
Last summer, Pfizer Inc. announced it was selling the surgical ophthalmic business acquired in the acquisition of Pharmacia Inc. (See Ophthalmology Times, Sept. 1, 2003 issue, Page 3).
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
OSRX expands medication sizes and adds direct-to-patient post-op kits
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes